Ausgabe 4/2013
Inhalt (16 Artikel)
Multiple Myeloma (R Niesvizky, Section Editor)
Management of Double-Refractory Multiple Myeloma
Jason P. Meadows, Tomer M. Mark
Multiple Myeloma (R Niesvizky, Section Editor)
Incorporating Novel Agents in the Management of Elderly Myeloma Patients
Tommasina Guglielmelli, Antonio Palumbo
Multiple Myeloma (R Niesvizky, Section Editor)
New Approaches to Smoldering Myeloma
María-Victoria Mateos, Jesús F. San Miguel
Multiple Myeloma (R Niesvizky, Section Editor)
Multiple Myeloma: Defining the High-Risk Patient and Determining the Optimal Treatment Strategy
Jordan Schecter, Suzanne Lentzsch
Multiple Myeloma (R Niesvizky, Section Editor)
Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: What Place, If Any?
Sergio Giralt, Guenther Koehne
Multiple Myeloma (R Niesvizky, Section Editor)
New Insights and Modern Treatment of AL Amyloidosis
Chakra P. Chaulagain, Raymond L. Comenzo
Myeloproliferative Disorders (JJ Kiladjian, Section Editor)
Genetic Basis of MPN: Beyond JAK2-V617F
Nicole C. C. Them, Robert Kralovics
Myeloproliferative Disorders (JJ Kiladjian, Section Editor)
Are MPNs Vascular Diseases?
Guido Finazzi, Valerio De Stefano, Tiziano Barbui
Myeloproliferative Disorders (JJ Kiladjian, Section Editor)
Preclinical Models for Drug Selection in Myeloproliferative Neoplasms
Niccolò Bartalucci, Costanza Bogani, Alessandro M. Vannucchi
Myeloproliferative Disorders (JJ Kiladjian, Section Editor)
The New Landscape of Therapy for Myelofibrosis
Krisstina Gowin, Robyn Emanuel, Holly Geyer, Ruben A. Mesa
Myeloproliferative Disorders (JJ Kiladjian, Section Editor)
WHO Classification of Myeloproliferative Neoplasms (MPN): A Critical Update
Hans Michael Kvasnicka
Myeloproliferative Disorders (JJ Kiladjian, Section Editor)
Molecular Classification of Myeloproliferative Neoplasms—Pros and Cons
Moosa Qureshi, Claire Harrison
Myelodysplastic Syndromes (M Sekeres, Section Editor)
There’s Risk, and Then There’s RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes
Amer M. Zeidan, Rami S. Komrokji
Myelodysplastic Syndromes (M Sekeres, Section Editor)
Standardizing the Initial Evaluation for Myelodysplastic Syndromes
Danielle Marshall, Gail J. Roboz
Myelodysplastic Syndromes (M Sekeres, Section Editor)
Febrile Neutropenia in Hematologic Malignancies
Michael K. Keng, Mikkael A. Sekeres
Myelodysplastic Syndromes (M Sekeres, Section Editor)
When to Transplant MDS, and What to Do When Transplant Fails
Katja Sockel, Uwe Platzbecker